AR and prostate carcinoma: Furthermore, PROTAC 8 reduced AR levels in prostate cancer-resistant cells LNCaP (approximately 3.5-fold at 10 μM), while AR was substantially increased in cells treated with enzalutamide (approximately 17.5-fold at 10 μM).